Amplia Therapeutics (ASX:ATX) has announced a milestone in its ACCENT clinical trial in frontline patients with pancreatic cancer.

The Australian pharmaceutical company is advancing a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, and says its now enrolled the first cohort of patients.

Amplia says the first stage of the trial is designed to test ascending doses of AMP945 given in combination with standard chemotherapy.

It also says it now has seven clinical trial sites and that there?s been a lot of interest in it, so expects recruitment rates will accelerate as the trial builds momentum.